Tidemark LLC Lowers Holdings in DexCom, Inc. (NASDAQ:DXCM)

Tidemark LLC trimmed its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 34.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 1,121 shares of the medical device company’s stock after selling 600 shares during the quarter. Tidemark LLC’s holdings in DexCom were worth $87,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Versant Capital Management Inc purchased a new stake in shares of DexCom during the fourth quarter valued at approximately $25,000. Private Trust Co. NA lifted its position in DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 245 shares in the last quarter. Larson Financial Group LLC boosted its stake in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares during the last quarter. Heck Capital Advisors LLC bought a new stake in shares of DexCom in the 4th quarter worth $38,000. Finally, SBI Securities Co. Ltd. purchased a new position in shares of DexCom in the fourth quarter worth $49,000. 97.75% of the stock is currently owned by institutional investors.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $70.69 on Friday. The firm’s 50 day simple moving average is $83.99 and its two-hundred day simple moving average is $76.89. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The company has a market capitalization of $27.62 billion, a P/E ratio of 49.43, a P/E/G ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Research analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analysts Set New Price Targets

DXCM has been the topic of several recent analyst reports. Morgan Stanley increased their price objective on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Wells Fargo & Company restated an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Canaccord Genuity Group lifted their target price on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Finally, Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and increased their price target for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

Insider Transactions at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 104,657 shares of company stock valued at $8,019,422 over the last 90 days. Company insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.